熱門資訊> 正文

Tempus获得FDA批准Tempus ECG-Low EF

2025-07-16 23:19

Tempus AI (NASDAQ:TEM) said that it has obtained 510((k)) clearance from the U.S. FDA for Tempus ECG-Low EF software.
This software utilizes artificial intelligence to help identify patients who may be experiencing a low left ventricular ejection fraction, a measure of heart function.
With this new clearance, Tempus ECG-Low EF becomes the second AI-powered ECG device approved by the FDA of the company, following the earlier approval of Tempus ECG-AF.

More on Tempus AI

Tempus AI: High-Growth And High-Risk
Tempus AI Is Well Worth Its Price Tag
I'm Still Bullish On Tempus AI
Personalis expands Tempus deal to include colorectal cancer testing
Tempus AI proposes $400M convertible debt offering

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。